BiPER Therapeutics is focused on developing innovative cancer treatments through its unique approach of targeting the BiP protein, which plays a critical role in the endoplasmic reticulum (ER) stress response in cancer cells. Their lead candidate, BPR001, is a first-in-class small molecule that selectively binds to GRP78/BiP, inducing unresolved ER stress that leads to cancer cell death via apoptosis and autophagy. This mechanism is particularly effective because cancer cells often rely on BiP to survive adverse conditions such as hypoxia and nutrient deprivation. By inhibiting BiP, BPR001 aims to overcome the resistance mechanisms that many tumors develop against standard therapies, thereby improving treatment outcomes for patients with various cancer types.

In addition to BPR001, BiPER is also developing BPR002, another first-in-class small molecule that induces ER stress while exhibiting immunomodulatory properties. This candidate is designed to enhance the immune system's ability to recognize and eliminate malignant cells, addressing the challenges posed by the tumor microenvironment that often hinders anti-tumor immunity. Both compounds are supported by extensive preclinical data demonstrating their efficacy and tolerability, positioning BiPER Therapeutics at the forefront of novel cancer treatment strategies that aim to bridge significant gaps in current therapeutic options.

France

BiPER Therapeutics is developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer through the modulation of the endoplasmic reticulum stress.

BiPER Therapeutics

Company Details